Editas Medicine Inc. (EDIT) Director Sells $337,450.80 in Stock
Editas Medicine Inc. (NASDAQ:EDIT) Director Kevin Bitterman sold 21,480 shares of the business’s stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $15.71, for a total transaction of $337,450.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Kevin Bitterman also recently made the following trade(s):
- On Tuesday, November 15th, Kevin Bitterman sold 88,900 shares of Editas Medicine stock. The stock was sold at an average price of $16.96, for a total transaction of $1,507,744.00.
Editas Medicine Inc. (NASDAQ:EDIT) traded down 1.70% on Monday, reaching $15.03. 274,006 shares of the company traded hands. The stock’s 50 day moving average price is $14.51 and its 200 day moving average price is $21.70. Editas Medicine Inc. has a one year low of $12.43 and a one year high of $43.99. The company’s market capitalization is $535.58 million.
Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, November 7th. The company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.05. Editas Medicine had a negative net margin of 1,184.46% and a negative return on equity of 59.22%. The firm earned $1 million during the quarter, compared to analysts’ expectations of $1 million. The firm’s quarterly revenue was up 49.3% on a year-over-year basis. On average, equities research analysts predict that Editas Medicine Inc. will post ($2.49) EPS for the current fiscal year.
Several equities research analysts have recently commented on EDIT shares. Jefferies Group reissued a “buy” rating on shares of Editas Medicine in a research report on Monday, August 22nd. Zacks Investment Research upgraded shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, September 20th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Editas Medicine presently has a consensus rating of “Buy” and a consensus target price of $30.75.
Several large investors have recently bought and sold shares of the company. FMR LLC raised its position in shares of Editas Medicine by 0.9% in the second quarter. FMR LLC now owns 5,452,061 shares of the company’s stock valued at $133,030,000 after buying an additional 50,031 shares during the last quarter. Flagship Ventures Fund IV General Partner LLC acquired a new position in shares of Editas Medicine during the second quarter valued at about $120,910,000. Price T Rowe Associates Inc. MD raised its position in shares of Editas Medicine by 32.5% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,874,396 shares of the company’s stock valued at $25,267,000 after buying an additional 460,280 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Editas Medicine by 159.0% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 170,739 shares of the company’s stock valued at $2,302,000 after buying an additional 104,808 shares during the last quarter. Finally, BlackRock Fund Advisors raised its position in shares of Editas Medicine by 2.8% in the second quarter. BlackRock Fund Advisors now owns 163,385 shares of the company’s stock valued at $3,987,000 after buying an additional 4,466 shares during the last quarter. 60.89% of the stock is owned by hedge funds and other institutional investors.
About Editas Medicine
Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.
Receive News & Stock Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related stocks with our FREE daily email newsletter.